- Home
- OP vs COCP Comparison
OP vs COCP Comparison
Compare OP & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- COCP
- Stock Information
- Founded
- OP 2021
- COCP 2006
- Country
- OP Greece
- COCP United States
- Employees
- OP N/A
- COCP N/A
- Industry
- OP
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- COCP Health Care
- Exchange
- OP Nasdaq
- COCP Nasdaq
- Market Cap
- OP 14.3M
- COCP 15.4M
- IPO Year
- OP N/A
- COCP N/A
- Fundamental
- Price
- OP $0.19
- COCP $1.60
- Analyst Decision
- OP
- COCP Strong Buy
- Analyst Count
- OP 0
- COCP 1
- Target Price
- OP N/A
- COCP $6.00
- AVG Volume (30 Days)
- OP 16.4M
- COCP 26.3K
- Earning Date
- OP 08-06-2025
- COCP 08-13-2025
- Dividend Yield
- OP N/A
- COCP N/A
- EPS Growth
- OP N/A
- COCP N/A
- EPS
- OP N/A
- COCP N/A
- Revenue
- OP $25,702,000.00
- COCP N/A
- Revenue This Year
- OP N/A
- COCP N/A
- Revenue Next Year
- OP N/A
- COCP N/A
- P/E Ratio
- OP N/A
- COCP N/A
- Revenue Growth
- OP 35.58
- COCP N/A
- 52 Week Low
- OP $0.17
- COCP $1.12
- 52 Week High
- OP $3.17
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- OP 33.59
- COCP 49.83
- Support Level
- OP $1.49
- COCP $1.59
- Resistance Level
- OP $2.50
- COCP $1.68
- Average True Range (ATR)
- OP 0.26
- COCP 0.12
- MACD
- OP -0.18
- COCP -0.01
- Stochastic Oscillator
- OP 0.73
- COCP 28.57
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).